Novel RANKL DE-loop mutants antagonize RANK-mediated osteoclastogenesis by Wang, Yizhou et al.
  
 University of Groningen
Novel RANKL DE-loop mutants antagonize RANK-mediated osteoclastogenesis
Wang, Yizhou; van Assen, Aart H G; Dos Reis, Carlos Ricardo Rodrigues; Setroikromo, Rita;





IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2017
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Wang, Y., van Assen, A. H. G., Dos Reis, C. R. R., Setroikromo, R., van Merkerk, R., Boersma, Y. L., ...
Quax, W. J. (2017). Novel RANKL DE-loop mutants antagonize RANK-mediated osteoclastogenesis. Febs
Journal, 284(15), 2501-2512. https://doi.org/10.1111/febs.14142
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
Novel RANKL DE-loop mutants antagonize RANK-mediated
osteoclastogenesis
Yizhou Wang†, Aart H.G. van Assen†, Carlos R. Reis, Rita Setroikromo, Ronald van Merkerk,
Ykelien L. Boersma, Robbert H. Cool and Wim J. Quax





W. J. Quax, Department of Chemical and
Pharmaceutical Biology, Groningen
Research Institute of Pharmacy, University
of Groningen, A. Deusinglaan 1, 9713 AV
Groningen, The Netherlands
Fax: +31 50 363 3000
Tel: +31 50 363 2558
E-mail: w.j.quax@rug.nl
†Both authors equally contributed to this
manuscript
(Received 26 January 2017, revised 12 May
2017, accepted 14 June 2017)
doi:10.1111/febs.14142
Bone is a dynamic tissue that is maintained by continuous renewal. An
imbalance in bone resorption and bone formation can lead to a range of
disorders, such as osteoporosis. The receptor activator of NF-jB
(RANK)–RANK-ligand (RANKL) pathway plays a major role in bone
remodeling. Here, we investigated the effect of mutations at position I248
in the DE-loop of murine RANKL on the interaction of RANKL with
RANK, and subsequent activation of osteoclastogenesis. Two single
mutants, RANKL I248Y and I248K, were found to maintain binding and
have the ability to reduce wild-type RANKL-induced osteoclastogenesis.
The generation of RANK-antagonists is a promising strategy for the explo-
ration of new therapeutics against osteoporosis.
Introduction
Bone is a dynamic tissue that has multiple functions,
including support of muscles, protection of vital organs,
and fostering hematopoietic marrow [1,2]. Under nor-
mal conditions, bone homeostasis is achieved by contin-
uous renewal, mediated by two processes: bone
resorption by osteoclasts and bone formation by osteo-
blasts [3]. An imbalance in bone resorption and forma-
tion can cause bone-associated diseases: when the
activity of osteoclasts exceeds that of osteoblasts, osteo-
porosis will be developed. In contrast, osteopetrosis will
occur when osteoblastic activity exceeds [4].
Osteoclastogenesis is regulated by a cytokine system,
consisting of three major proteins: receptor activator of
nuclear factor-jB (RANK), RANK-ligand (RANKL),
and osteoprotegerin (OPG) [5]. The binding between
RANKL on the surface of osteoblast cells and the
RANK on osteoclast precursor cells will trigger activa-
tion of several transcription factors and enzymes that
induce osteoclast maturation and bone resorption. OPG
is a soluble decoy receptor, acting as a natural antagonist
of RANKL [6]. The RANK–RANKL pathway plays an
important role in both physiological and pathological
bone development. Therefore, this signaling pathway is a
promising target in bone-related diseases [3].
Receptor activator of nuclear factor-jB-ligand is a
member of the tumor necrosis factor (TNF)-superfamily,
Abbreviations
mRANK, murine RANK; mRANKL, murine RANK-ligand; OPG, osteoprotegerin; RANKL, receptor activator of nuclear factor-jB-ligand; RANK,
receptor activator of nuclear factor-jB; sfGFP-RANKL, superfolder green fluorescent protein-RANKL fusion protein; SPR, surface plasmon
resonance; TNF, tumor necrosis factor; TNF-a, tumor necrosis factor a; TNF-R1, tumor necrosis factor receptor 1; TNF-R2, tumor necrosis
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a group of cytokines involved in cell proliferation and
cell death [7]. The TNF-superfamily consists of 19 multi-
meric ligands interacting with cognate receptor mole-
cules; most of them require trimerization to initiate their
signaling cascade [8]. Ligands belonging to the
TNF-superfamily are mostly type II transmembrane gly-
coproteins, containing a C-terminal, receptor-interacting
ectodomain, a transmembrane domain, and anN-terminal
intracellular tail [4]; the extracellular domain can be
either cleaved off by the proteolytic activity of metallo-
proteases or produced by alternative splicing [9,10].
Three-dimensional structures of TNF-a, TRAIL,
and RANKL alone and in complex with their respec-
tive receptors have revealed very similar overall
structures that comprise unique conserved elements
involved in receptor binding [11–18]. One of these ele-
ments is the so-called DE-loop. There is a conserved
tyrosine in the DE-loop of all TNF-ligands, with the
exception of an arginine in CD40L and an isoleucine
in RANKL. Interestingly, variants of human TNF-a
with mutated DE-loop residues including the semicon-
served residue Y87 were shown to be receptor
antagonists: some mutants selectively bound to human
TNF-receptor 1 (TNF-R1) and not TNF-receptor 2
(TNF-R2), while inhibiting wild-type TNF-a-mediated
effects via TNF-R 1 [13]. Comparing the 3D structure
of the antagonistic TNF-R1-selective mutant with that
of wild-type TNF-a, it was concluded that the Y87H
mutation changed the binding mode of the DE-loop to
TNF-R1 from a hydrophobic to an electrostatic inter-
action [13]. In murine RANKL, mutation of the equiv-
alent residue I248 to aspartate resulted in an eightfold
lower ED50 [12]. In contrast, another 3D structure has
led to the suggestion that the DE-loop may not be
critical for mRANKL–mRANK binding [11,19].
Here we have investigated the effect of mutations of
the I248 residue in the mRANKL DE-loop on the
binding to mRANK and on subsequent osteoclastogen-
esis. Our results show that RANKL mutants I248Y
and I248K have the ability to reduce RANKL-induced
osteoclastogenesis. Thus, mutagenesis at position I248
of the DE-loop region can form the basis of a general
strategy to create RANK-antagonists for the RANKL–
RANK pathway, paving the way to novel osteoporosis
treatments.
Results
In silico mutagenesis of mRANKL demonstrates
importance of position I248
Several 3D structures of mRANKL have been
described previously [4,11,12,20,21]. The 3D structure
of mRANK in complex with mRANKL (Protein Data
Bank accession code 4GIQ) was used for in silico
mutagenesis at position I248 in order to estimate dif-
ferences in DDGi binding to RANK between RANKL
mutants and wild-type RANKL (WT RANKL)
(Fig. 1A,B). A similar strategy has allowed us in the
past to successfully generate variants of hTRAIL with
desired properties, such as enhancement of affinity and
change of receptor selectivity [22–24]. As shown in
Fig. 1B, the RANK residues surrounding I248 of
RANKL are hydrophilic, including D49, T50, N52,
E53, and E54, suggesting that the surface interaction
between the DE-loop of RANKL and RANK is pre-
dominantly hydrophilic. This is different from the
binding between TNF and TNF-R1, where Y87 of
TNF is buried in a hydrophobic ‘pocket’ of the TNF-
R1. The importance of RANKL residue I248 for the
interaction with RANK was investigated by in silico
mutagenesis. The effects of variation at position 248 of
RANKL on the calculated DDGi are shown in Fig. 1C.
Overall, our data indicate that substitution by other
amino acids results in a strong effect on binding of
RANKL to RANK, either positive or negative, sug-
gesting that this residue is indeed important for bind-
ing. Given the overall estimated effects on binding
energies between RANKL and RANK, we decided to
focus on and construct a subset of RANKL mutants.
I248Y was chosen because of the conserved tyrosine at
the same position in the DE-loop of TNF-ligands and
its calculated large difference in DDGi (Fig. 1C); I248K
because this mutation also has a predicted large effect
on the DDGi, plus it is homologous to the arginine
found at this position in TNF-ligand family member
CD40L; and finally I248D was chosen as it was previ-
ously reported to have an eightfold lower ED50 com-
pared to WT RANKL [12]. As the interaction between
the DE-loop of RANKL and RANK is mainly hydro-
philic, all the hydrophobic mutations including I248W
were not taken into consideration.
RANKL mutations I248Y and I248K show
increased binding affinity to RANK
After expression, purification, and characterization of
WT RANKL and mutants, we determined their affini-
ties to RANK by surface plasmon resonance (SPR).
Using a CM4 sensor chip and a low density of
RANK-Fc [< 60 response units (RU)], we were able to
measure the interaction between one trimeric RANKL
molecule binding to one RANK-Fc monomer [8].
Indeed, the sensorgrams for WT RANKL, I248Y,
I248K, and I248D all show a ~ 1 : 1 binding ratio
(varying between 0.9 and 1.2) (Fig. 2). Hence, the data
2502 The FEBS Journal 284 (2017) 2501–2512 ª 2017 The Authors. The FEBS Journal published by John Wiley & Sons Ltd on behalf of
Federation of European Biochemical Societies.
RANKL variants antagonizing osteoclastogenesis Y. Wang et al.
could be fitted with a 1 : 1 Langmuir fitting model
and the kinetic parameters were calculated [8]. As
shown in Table 1, I248Y and I248K showed approxi-
mately three- to fourfold higher affinities to the target
receptor in comparison to WT RANKL. This was
mainly caused by an increase in the association rate
constant (ka). The dissociation rate constants (kd) of
I248Y and I248K were comparable to WT RANKL.
Mutant I248D showed a lower affinity to RANK-Fc
compared to WT RANKL, which is mainly due to a
much higher dissociation rate. Taken together, these
results are consistent with the previous in silico predic-
tions and they further confirm that the I248 residue
indeed plays an important role in RANKL–RANK
binding.
RANKL mutants compete for binding of WT
RANKL to RANK and form high-order complexes
with their receptor
To further assess whether the mutants compete with
WT RANKL for binding, we performed a competitive
ELISA assay, in which wells coated with RANK-Fc
were incubated with both WT RANKL and RANKL
variants. Our competitive ELISA results (Fig. 3)
showed that increasing concentrations of both I248K
and I248Y can efficiently compete with WT RANKL
for RANK-Fc binding at physiological concentrations.
However, RANKL I248D could only partially com-
pete with WT RANKL at concentrations over
1000 nM, which is in accordance with the lowered
affinity of RANKL I248D to RANK-Fc compared to
WT RANKL.
Given that signaling of several TNF cytokines has
been shown to require receptor oligomerization, we
also tested whether mutants I248Y, I248K, and I248D
could form multimeric complexes with RANK using
high densities of RANK-Fc in SPR. As shown in
Fig. 4, using the number of RU of bound RANK-Fc,
we could estimate the ratio of complex formation (the
number of trimeric RANKL units bound to mono-
meric RANK-Fc) using equation 1 (see Experimental
Procedures). A binding ratio of 1 : 3.07  0.01 was
found for WT RANKL. For RANKL mutants I248Y,
I248K, and I248D, mean binding ratios were
1 : 3.03  0.04, 1 : 2.99  0.02, and 1 : 3.12  0.01,
respectively. These results imply that the mutants, as
WT RANKL, form a trimer–trimer complex with the
RANK receptor.
RANKL mutants antagonize the biological
activity of WT RANKL
We next tested the effect of RANKL mutants I248D,
I248K, and I248Y on osteoclastogenesis by assessing
their ability to induce multinucleation (three or more
nuclei per cell) in osteoclast precursor murine RAW
264.7 cells and by testing their capability to inhibit
WT RANKL (Fig. 5A, and Tables S1 and S2). Micro-
scope photographs of osteoclasts from different
Fig. 1. Structural representation of the
binding interface of the RANKL DE-loop
with RANK and binding energy predictions
for I248 mutants, made using Discovery
Studio 4.5. (A) Refined structure of RANKL
(orange) in complex with RANK (shown in
hydrophilicity contact surface). The various
strands and loops of RANKL are shown in
orange and the DE-loop of RANKL is shown
in yellow. The model was derived from the
3D structure of the murine RANKL–RANK
complex (PDB code 4GIQ). (B) Detailed
view of RANK residues in close proximity to
residue I248 of RANKL. (C) Predicted
differences in binding energy (DDGi) of I248
variants binding to RANK when compared
with WT RANKL. The change in energy is
measured in kcalmol1. A negative DDGi
value indicates an improvement in receptor
binding, whereas a positive DDGi value
indicates a deterioration in receptor binding.
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treatments with RANKL variants (50 ngmL1) only,
WT RANKL (50 ngmL1), or a combination of both
are shown in Fig. 5A. Single treatment with WT
RANKL caused osteoclast formation to a large extent
and induced formation of giant multinucleated cells
(two or more clusters of multinuclei per cell) which
can cover large areas of the wells. RANKL variants
themselves were also capable of inducing osteoclast
formation, although the number of osteoclasts formed
was lower than that induced by WT RANKL. Compe-
tition of either RANKL I248Y or I248K with
50 ngmL1 WT RANKL led to a reduction in both
number and size of osteoclasts, while the competitive
effect of RANKL I248D was less than that of I248Y
and I248K. Importantly, single treatment with each of
the three mutants induced less osteoclastogenesis com-
pared to treatment with WT RANKL at all concentra-
tions measured (Fig. 5B–D). The high-affinity mutants
I248Y and I248K reached a maximum level at approx-
imately 50 ngmL1, which is 70 and 80% of that of
WT RANKL, respectively (Fig. 5B,C). In contrast, the
low-affinity mutant I248D only reached up to 40% of
the osteoclastogenic effect of WT RANKL even at the
highest concentration of 150 ngmL1 (Fig. 5D).
Cotreatment of RAW 264.7 cells with WT RANKL
and high-affinity mutants I248Y or I248K led to a
reduction in the level of osteoclastogenesis by 30–40%
already at low concentration of mutant RANKL, with
Fig. 2. Typical SPR sensorgrams obtained for binding between RANK-Fc and RANKL variants. The sensorgrams are obtained at receptor
density < 60 RU to establish a 1 : 1 binding ratio. Depicted are (A) WT RANKL, (B) RANKL variant I248Y, (C) RANKL variant I248K, and (D)
RANKL variant I248D. Injection of RANKL (0–20.48 nM) is marked with a double-headed arrow. After injection a buffer effect is visible for
the higher concentrations used. Dissociation is followed up for 1000 s.
Table 1. Binding kinetics of the RANKL variants and WT RANKL to
murine RANK-Fc as measured by surface plasmon resonance.
ka106 (M1s1) kd104 (s1) KD (pM)
WT 4.3  1.5 1.5  0.4 38  2
I248Y 15.7  7.7 1.3  0.7 8  3
I248K 17.1  1.1 1.5  0.4 9  2
I248D 8.0  0.9 4.2  0.6 53  7
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no further reduction at higher concentrations (Fig. 5B,
C). In contrast, the low-affinity mutant I248D only
showed a reduction of the osteoclastic potential of WT
RANKL at high concentrations (> 50 ngmL1)
(Fig. 5D).
Does exchange of RANKL subunits play a role in
inhibition of WT RANKL-induced
osteoclastogenesis?
In our studies, we showed inhibition of WT RANKL-
induced osteoclastogenesis in the murine RAW 264.7
cell line by RANKL variants I248K and I248Y
(Fig. 5). Although they themselves can also cause
osteoclast formation, the numbers of osteoclasts are
lower than those of WT RANKL (50 ngmL1). The
increased affinities of these mutants can explain the
results of the inhibition experiments: both mutants
showed higher affinities to RANK-Fc than WT
RANKL (Fig. 2), which can make them compete
efficiently with WT RANKL to occupy RANK
and induce less osteoclastogenesis. An alternative
explanation may be that the subunits of RANKL are
interchanged, allowing formation of heterotrimeric
RANKL molecules that are no longer able to activate
RANK. To confirm or refute this hypothesis, we
mixed purified sfGFP-WT RANKL with WT RANKL
at equimolar ratio and incubated this for either 24 h
at 37 °C or 44 h at 4 °C. The protein samples were
loaded onto a size exclusion column while the absor-
bance was followed at 280 and 475/488 nm (Fig. 6).
The trimeric fusion protein sfGFP-WT RANKL with
its higher molecular weight eluted at approximately
12 mL showing absorbance at both wavelengths,
whereas WT RANKL eluted at approximately
14.8 mL, showing only absorbance at 280 nm. Mixing
of the two trimeric proteins did not result in shifting
peaks, demonstrating that no exchange occurred dur-
ing the incubation (Fig. 6).
Discussion
Bone homeostasis is achieved by continuously renew-
ing the tissue [6]. Loss of bone remodeling homeostasis
can lead to a range of disorders, including osteoporo-
sis [6], bone lesions associated with rheumatoid arthri-
tis [25], Paget’s disease [26], and malignancy-induced
bone diseases [27]. Due to the important role of the
RANK–RANKL pathway in the bone remodeling
process [5], interfering with their interaction is a
promising strategy for therapeutic intervention. Ini-
tially, OPG-Fc was developed as a RANKL scavenger
[28]; as OPG cross reacts with TRAIL, recently OPG
variants lacking TRAIL binding were developed,
showing significantly reduced osteoclastogenesis [29].
RANKL-targeted peptides were also developed and
confirmed to prevent bone loss and inflammation in
rheumatoid arthritis in vivo [19,30]. Finally, deno-
sumab, an FDA-approved RANKL-specific antibody,
was developed and is currently used in the treatment
of osteoporosis and bone metastases [19]. Denosumab
inhibits osteoclastogenesis by scavenging RANKL thus
inhibiting receptor interaction. In contrast, we focused
on novel RANKL variants, which will be of interest as
these are blocking the receptor directly.
Three-dimensional structures of TNF-TNF-R1 and
TRAIL-DR5 complexes show a conserved tyrosine
residue in the DE-loop of ligands, which induces a
hydrophobic interaction with loop 1 of the receptors
[15,31]. Mukai et al. [32] created a series of receptor-
selective TNF-a mutants with full bioactivity by using
the phage display technique; the results showed that
all active TNF-R1-selective mutants retained Y87, sug-
gesting that Y87 is an essential residue for receptor
binding. Furthermore, TNF-a mutation Y87H was
generated as a part of a TNF-R1-selective antagonist,
and Y87H was found to change the binding mode of
the DE-loop from a hydrophobic to an electrostatic
interaction [13]. In silico calculation of the effects of
mutations of RANKL residue I248, which is homolo-
gous to TNF-a Y87, on the interaction with its
Fig. 3. Competitive ELISA performed with 10 nM sfGFP-WT
RANKL and increasing concentrations (0–8000 nM) of variants
I248Y (red circles), I248K (blue squares), and I248D (orange
triangles). Bound sfGFP-WT RANKL was detected by incubation
with a murine anti-GFP antibody and a secondary anti-mouse HRP-
conjugated antibody. The signal was quantified using the One-step
Turbo TMB reagent and absorbance was measured at 450 nm
using a spectrophotometer. The percentage of sfGFP-WT RANKL
bound was measured relative to the binding of 10 nM sfGFP-WT
RANKL alone. The log concentration of the RANKL variants is
displayed on the x-axis. The error bars reflect the standard
deviation (SD) of three independent experiments.
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receptor RANK, suggested that mutagenesis of the
I248 residue of RANKL has strong effect on binding
of RANKL to RANK.
We have focused on three mutations on position
248: I248Y, I248K, and I248D. Detailed analysis of
the interaction of RANKL proteins with RANK using
SPR showed an increased affinity for mutants I248K
and I248Y and a decreased affinity for I248D (Fig. 2
and Table 1). In accordance, competitive ELISA con-
firmed that RANKL I248Y and I248K can efficiently
compete with WT RANKL for binding to RANK,
whereas I248D cannot (Fig. 3). In line with these
results, structural analysis of the impact of these muta-
tions shows that the positively charged lysine on posi-
tion 248 may interact with the negatively charged E54
residue on the RANK surface. Mutation I248Y could
also result in an extra hydrogen bond and strength-
ened van der Waals forces, also reinforcing the binding
of RANKL and RANK. The lower affinity for RANK
that we measured for I248D can be explained by an
electrostatic repulsion with E54 residue in RANK.
High-affinity mutants RANKL I248Y and I248K are
still able to induce osteoclastogenesis but to a 20–30%
lower maximum thanWTRANKL, whereas low-affinity
mutant I248D does not even reach 40% of this maximum
activation level even at 150 ngmL1 (Fig. 5). Interest-
ingly, the high-affinity mutants were able to reduce WT
RANKL-mediated osteoclastogenesis already at low
concentrations, whereas I248D shows a dose-dependent
reduction of theWTRANKL signal up to the concentra-
tion of 150 ngmL1 (Fig. 5). All three mutants showed
higher association rate constants (Table 1) allowing
them to bind faster to the receptor than WT RANKL.
Although high-affinity mutants I248K and I248Y have
similar dissociation rate constants as WT RANKL, low-
affinity mutant I248D has a higher dissociation rate
constant (Table 1). The latter one leads to a less stable
complex with RANK, which can explain why this mutant
in itself is not very biologically active and why it reduces
WT RANKL activity only at high concentrations
(Fig. 5D). A similar explanation was formulated for
antagonistic TNF-amutation Y87H [13].
Fig. 4. Typical SPR sensorgrams to check trimer–trimer binding of RANKL and RANK-Fc. Depicted are the injection phases of RANK-Fc
followed by the injection phase of WT RANKL or mutants. Regeneration (reg.) is visible at the end. With the number of response units (RU)
bound, the ratio of complex formation, i.e., the number of trimeric RANKL units bound to monomeric RANK-Fc was estimated. Shown are
the injections of (A) WT RANKL, (B) I248Y, (C) I248Y, and (D) I248D, leading to binding to RANK-Fc.
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Our RANKL mutants can reduce WT RANKL
activity by competing in binding to RANK, resulting
in a reduction in biological activity to the level of the
mutants themselves. What could be an explanation for
this lower biological activity? In a molecular dynamics
study on binding between TNF-ligand family member
TRAIL and its death receptor DR5, Wassenaar et al.
[33] proposed that through binding to TRAIL the con-
formational freedom of extracellular binding domains
of DR5 was strongly restricted; this might also influ-
ence the stability of the intracellular death complex.
Furthermore, Neumann et al. [34] showed that the sig-
naling capabilities of the death receptors DR4 and
DR5 do not only depend on binding of TRAIL but
the transmembrane domains together with their adja-
cent stalk regions also control the signaling strength.
Likewise, the transmembrane domain and adjacent
extracellular stalk regions of RANK could play a simi-
lar role. RANKL may also play a role in controlling
the conformational freedom of the extracellular
domains of RANK. Mutants RANKL I248Y and
I248K may slightly change the conformation of the
RANKL–RANK complex, thus influencing the con-
formational freedom of RANK extracellular domains
and subsequently the orientation of intracellular
domains, which further influences the recruitment of
downstream effector proteins.
In conclusion, our data show that the DE-loop is of
importance for osteoclastogenesis and can be explored
for the creation of new ligands with inhibitory proper-
ties. Given the importance of the DE-loop for
RANK–RANKL signaling, the newly created mutants
I248Y and I248K can form a starting point for novel
therapeutic proteins in new osteoporosis treatments.
Experimental procedures
In silico calculations of the interaction energy of
RANK in complexes with RANKL I248 mutants
Simulations were performed using the available 3D structure
of murine RANKL in complex with RANK (Protein Data
Bank accession code 4GIQ) [4]. All calculations and
predictions were performed using BIOVIA Discovery studio
4.5. Briefly, the structures of RANKL and the I248 mutants
were refined using the CHARMm force field. For the mini-
mization of the receptor–ligand complex, the Smart Mini-
mizer was used with maximum steps of 2000 and RMS
gradient of 0.1, and Generalized Born with molecular vol-
ume (GBMW) was used as implicit solvation model. Pre-
dicted differences in RANK-binding energy (DDGi) of the
RANKL I248 mutants compared to WT RANKL were
determined through interaction energy calculation. The
change in energy was calculated in kcalmol1 and applies to
a single binding interface. A negative DDGi value indicates
an increase in receptor binding energy, whereas a positive
DDGi value indicates a decrease in receptor binding energy.
Site-directed mutagenesis, production, and
purification of the RANKL variants
cDNA encoding murine soluble RANKL (aa 160–316) was
introduced in a pET15b expression plasmid (Novagen,
Darmstadt, Germany) using the restriction sites NcoI and
BamHI (Fermentas, St. Leon, Lithuania). Mutations at posi-
tion 248 were introduced using megaprimers [35]. The PCR
product was digested using DpnI (Fermentas) to remove tem-
plate DNA and used for transformation of Escherichia coli
DH5a cells. Plasmid DNA was purified from an overnight
culture (Nucleospin, Macherey-Nagel, Du¨ren, Germany).
After confirming the introduction of mutations by DNA
sequencing, the plasmids were used for transformation of
E. coli BL21(DE3). Transformants selected using ampicillin
(Duchefa, Haarlem, the Netherlands) were grown overnight
at 37 °C in 1 x LB medium (Tryptone, NaCl, and yeast
extract all from Duchefa) containing 100 lgmL1 ampicillin.
This culture was used to inoculate a larger culture (1 : 100
dilution), which was grown for approximately 2 h to OD600
0.5, after which protein production was initiated by adding
1 mM IPTG (Duchefa), and continued for 16 h at 20 °C.
After harvesting cells by centrifugation and resuspending
at 3 mLg1 wet cells in buffer A containing 50 mM MES
pH 5.8 (Duchefa), 10% v/v glycerol (Duchefa), and 2 mM
dithiothreitol (Sigma, Saint Louis, MO, USA), the cells
were lysed by sonication. The RANKL proteins were
mainly soluble. Supernatants were firstly loaded on a 5 mL
cation exchange column (SP column, GE Healthcare,
Fig. 5. Relative number of osteoclasts obtained after treatment of murine RAW 264.7 cells with RANKL variants, WT RANKL or a
combination of both. (A) Microscope images and absolute numbers of normal and giant osteoclasts from different treatments with RANKL
variants (50 ngmL1) only, WT RANKL (50 ngmL1), or a combination of both at 2009 magnification. The yellow bars represent the
absolute numbers of normal osteoclasts, while the green bars represent the absolute numbers of giant osteoclasts; (B) Relative number of
osteoclasts for variant I248Y compared to WT RANKL; (C) Relative number of osteoclasts for variant I248K compared to WT RANKL; (D)
Relative number of osteoclasts for variant I248D compared to WT RANKL. The red bars represent the relative numbers of osteoclasts
treated with RANKL variant alone, and the blue bars represent the combination treatment of RANKL variants with WT RANKL (50 ngmL1).
The number of osteoclasts in the well treated with 50 ngmL1 WT RANKL only was set to 100%. Significance was calculated using a
Student’s t-test compared to untreated cells: (*) is P < 0.05 and (**) is P < 0.001. The error bars reflect the SD of three independent
experiments in triplicate. For WT RANKL alone, the error bar is the average SD over all separate experiments.
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Uppsala, Sweden) using buffer A. Buffer B, similar to A
but containing 2 M NaCl (Duchefa), was used to elute the
protein. Elution of the fractions containing RANKL
occurred with 300–400 mM NaCl. The presence of proteins
was confirmed by western blotting using an anti-mRANKL
antibody (R&D Systems, Minneapolis, MN, USA) and cor-
responding anti-goat-horse radish peroxidase (HRP) anti-
body (Biosource, Waltham, UK).
The obtained protein-containing fractions were pooled
and loaded onto a HiLoad Superdex75 16/60 size exclusion
chromatography column (GE Healthcare), using buffer A.
The retention volumes of the RANKL proteins corre-
sponded to the hydrodynamic radius of a trimeric complex.
The proteins were checked by SDS/PAGE to determine the
purity which was estimated to be more than 90% pure.
Concentrations were determined with the Coomassie Brad-
ford protein assay kit (Pierce, Rockford, IL, USA) using
bovine serum albumin (BSA, ThermoScientific, Rockford,
IL, USA) as a standard. The final yield of the variants was
approximately 2 mg purified protein per liter culture. When
calculating molarity, we used the molecular weight of
trimeric RANKL proteins.
Superfolder green fluorescent protein was amplified from
pQE30_sfGFP [36] by PCR, digested with NcoI/NcoI site
and ligated into the vector pET15b_WT RANKL to encode
sfGFP fused to the N terminus of WT RANKL. sfGFP-WT
RANKL was produced in BL21(DE3) cells similar to our
variants. For the purification of sfGFP-WT RANKL,
cleared cell lysate was firstly loaded onto a 5 mL anion
exchange column (Q column, GE Healthcare), using a buffer
of 20 mM Tris pH 8.5, 2 mM dithiothreitol, and 10% v/v glyc-
erol. Buffer B, similar to A but containing 2 M NaCl, was
used to elute the protein. Elution of the fractions containing
sfGFP-WT RANKL occurred at 300–500 mM NaCl. The
obtained protein-containing fractions were pooled and
loaded onto a 5 mL cation exchange column, followed by a
Fig. 6. Size exclusion chromatography for the determination of the potential exchange of RANKL subunits. (A) Chromatogram of WT RANKL
at 0 h; (B) Chromatogram for a mixture of WT RANKL and sfGFP-WT RANKL at concentrations of 12 lM each at 0 h; (C) Chromatogram for
a mixture of WT RANKL and sfGFP-WT RANKL after incubation for 24 h at 37 °C, and (D) for 44 h at 4 °C. Elution was monitored in mAU
at 280 nm (all proteins), 475 nm, and 488 nm (sfGFP fusion proteins).
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HiLoad Superdex200 16/60 size exclusion chromatography
column (GE Healthcare), and the purification steps were
similar with that of WT RANKL.
Kinetic analysis of complex formation between
trimeric RANKL and monomeric RANK-Fc
Binding between RANKL and RANK-Fc was determined
using a Biacore 3000 system (GE Healthcare). A CM4 chip
was directly coated with 70 lgmL1 protein A (Sigma),
making use of the amine coupling kit (GE Healthcare)
according to the manufacturer’s instructions. The amount of
immobilized protein A was typically around 1000 RU. Next,
murine RANK-Fc (R&D Systems) was captured at a low
density, never exceeding 60 RU. The flow rate used for
immobilization was 50 lLmin1. RANKL was injected at a
flow rate of 50 lLmin1 in concentrations between 0.01 nM
and 20.48 nM for 3 min. Dissociation of the formed complex
was followed up for 1000 s. HBS-N buffer (GE Healthcare)
with 0.005% v/v surfactant P20 (GE Healthcare, Uppsala,
Sweden) was used as a running buffer. The chip surface was
regenerated between cycles with two injections of 10 mM gly-
cine (Duchefa) pH 1.5 for 30 s each. The responses were cor-
rected for buffer effect and binding to the protein A chip
surface [8]. At low receptor densities, the data could be fitted
to a 1 : 1 Langmuir model using the BIAEVALUATION software
version 4.2 (GE Healthcare) [8].
Determination of trimer–trimer complexes using
SPR
To confirm whether a trimer–trimer complex could be
formed between RANKL and RANK, an SPR experiment
was set up as previously described [8]. RANK-Fc was cap-
tured at high density, > 1000 RU, on the surface of a CM5
chip by immobilized protein A. RANKL was injected at a
high concentration of 5000 nM with a flow rate of
10 lLmin1. After each cycle, the chip surface was regen-
erated as described above. With equation 1, the ratio of the
complex formation, n, can be calculated by measuring the
maximal response (Rmax) that can be reached by formation
of the complex ABn between trimeric RANKL (A; with
molecular weight MWA = 52.7 kDa) and monomeric
RANK-Fc (B; with molecular weight MWB = 60 kDa)
captured at density RUcaptured [8].
Rmax ¼ ½MWA=ðn MWBÞ RUcaptured ð1Þ
Competitive ELISA
Competition between selected RANKL mutants and WT
RANKL was determined using a competitive enzyme-linked
immunosorbent assay (ELISA). Murine RANK-Fc (Sigma)
was immobilized on a 96-well Microlon 600 plate (Greiner,
Frickenhausen, Germany) by incubating the wells with
25 nM RANK-Fc in 0.1 M NaHCO3 (Merck, Darmstadt,
Germany) buffer pH 8.6 overnight at 4 °C. Subsequently,
the wells were washed with Tris-buffered saline (TBS) buf-
fer including 0.05% v/v Tween 20 (TBST, Duchefa), pH
7.4, followed by a 2-h incubation at room temperature with
2% w/v BSA (Roche, Mannheim, Germany) in phosphate-
buffered saline (PBS), pH 7.4. After washing with TBST
buffer, the wells were incubated for 30 min at room temper-
ature with the RANKL variants I248K, I248Y, and I248D
at concentrations in the range of 0–8000 nM, mixed with
10 nM sfGFP-WT RANKL. After washing with TBST buf-
fer, bound sfGFP-WT RANKL was detected by incubation
with a murine anti-GFP antibody (Sigma) and a secondary
anti-mouse HRP-conjugated antibody (Millipore, Billerica,
MA, USA). The signal was quantified using the One-step
Turbo TMB reagent (ThermoScientific) and absorbance
was measured at 450 nm. The percentage of sfGFP-WT
RANKL bound was measured relative to the binding of
10 nM sfGFP-WT RANKL alone.
Inhibition of osteoclastogenesis
Cells from the murine leukemic monocyte macrophage cell
line RAW 264.7 were cultured as described before [37]. Cells
were subcultured every third or fourth day using a 1 : 10 dilu-
tion in fresh Dulbecco’s modified Eagle’s medium (Life Tech-
nologies, Carlsbad, CA, USA) containing 10% v/v fetal calf
serum (FCS, Life Technologies) and 2 mM penicillin/strepto-
mycin (Life Technologies). Cells were seeded at a density of
1000 cells per well in a 96-well plate (Greiner). At day 3, the
medium was changed to Alpha-MEM (Invitrogen, Carlsbad,
CA, USA) containing 2 mM penicillin/streptomycin and 10%
v/v FCS (Invitrogen); different concentrations of RANKL
were added, ranging from 3.1 to 150 ngmL1. Inhibition of
WT RANKL-induced osteoclastogenesis by RANKL
mutants was assessed via treatment of RAW 264.7 cells with
50 ngmL1 WT RANKL and a concentration range (3.1–
150 ngmL1) of a determined RANKLmutant. At day 5, the
medium was exchanged, and bothWTRANKL andRANKL
mutants were added using the same concentrations as
described for day 3. At day 7, osteoclastogenesis was deter-
mined using the tartrate resistance acid phosphatase (TRAP)
assay (Sigma) according to the manufacturer’s instructions.
The number of osteoclasts in the wells containing 50 ngmL1
WT RANKL was set to 100%, and the number of osteoclasts
in all other wells was calculated relative to this reference well.
Multinucleated (three or more nuclei) TRAP-positive cells
were considered as osteoclasts. Osteoclasts with two or more
clusters of multinuclei were considered as giant osteoclasts.
Determination of exchange of RANKL subunits
The exchange of RANKL subunits was determined using
size exclusion chromatography. WT RANKL and sfGFP-
WT RANKL at concentrations of 12 lM were incubated
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together in a 1 : 1 ratio for 24 h at 37 °C or for 44 h at
4 °C. After incubation, samples were loaded onto a Super-
dex 200 10/30 column (GE Healthcare) using buffer E
(20 mM sodium phosphate buffer pH 7.4, 10% v/v glyc-
erol,). Elution was monitored at 280 nm (all proteins) and
at 475/488 nm (sfGFP-WT RANKL); the chromatograms
were compared to that of a mixture of sfGFP-WT RANKL
and WT RANKL at 0 h.
Acknowledgements
Murine RAW 264.7 cells were a kind gift from J. Dok-
tor, Department of Pathology and Medical Biology,
University Medical Center Groningen, Groningen, The
Netherlands. This work was performed within the
framework of the Dutch Top Institute Pharma project
TNF-ligands in cancer (project nr. T3-112) and STW
grant 11056. YW is a recipient of a scholarship from
the Chinese Scholarship Council (CSC).
Author contributions
YW, AHGA, CRR, RS, RM, and RHC performed
experiments and analyzed data. YLB, RHC, and WJQ
planned the research and supervised the study. YW,
AHGA, YLB, RHC, and WJQ wrote the paper.
References
1 Kim J & Kim N (2016) Signaling pathways in
osteoclast differentiation. Chonnam Med J 52, 12–17.
2 Boyce BF & Xing L (2007) Biology of RANK,
RANKL, and osteoprotegerin. Arthritis Res Ther 9, S1.
3 Tanaka S, Nakamura K, Takahasi N & Suda T (2005)
Role of RANKL in physiological and pathological
bone resorption and therapeutics targeting the
RANKL-RANK signaling system. Immunol Rev 208,
30–49.
4 Nelson CA, Warren JT, Wang MWH, Teitelbaum SL &
Fremont DH (2012) RANKL employs distinct binding
modes to engage RANK and the osteoprotegerin decoy
receptor. Structure 20, 1971–1982.
5 Trouvin AP & Go€eb V (2010) Receptor activator of
nuclear factor-jB ligand and osteoprotegerin:
maintaining the balance to prevent bone loss. Clin
Interv Aging 5, 345–354.
6 Rachner T, Khosla S, Hofbauer L & Manuscript A
(2011) New horizons in osteoporosis. Lancet 377,
1276–1287.
7 Bodmer JL, Schneider P & Tschopp J (2002) The
molecular architecture of the TNF superfamily. Trends
Biochem Sci 27, 19–26.
8 Reis CR, van Assen AHG, Quax WJ & Cool RH
(2011) Unraveling the binding mechanism of trivalent
tumor necrosis factor ligands and their receptors. Mol
Cell Proteomics 10 (M110), 002808.
9 Walsh NC, Alexander KA, Manning CA, Karmakar S,
Karmakar SK, Wang JF, Weyand CM, Pettit AR &
Gravallese EM (2013) Activated human T cells express
alternative mRNA transcripts encoding a secreted form
of RANKL. Genes Immun 14, 336–345.
10 Ikeda T, Kasai M, Utsuyama M & Hirokawa K (2001)
Determination of three isoforms of the receptor
activator of nuclear factor-kappaB ligand and their
differential expression in bone and thymus.
Endocrinology 142, 1419–1426.
11 Liu C, Walter TS, Huang P, Zhang S, Zhu X,Wu Y,
Wedderburn LR, Tang P, Owens RJ, Stuart DI et al. (2010)
Structural and functional insights of RANKL-RANK
interaction and signaling. J Immunol 184, 6910–6919.
12 Lam J, Nelson CA, Ross FP, Teitelbaum SL &
Fremont DH (2001) Crystal structure of the TRANCE/
RANKL cytokine reveals determinants of receptor-
ligand specifity. J Clin Invest 108, 971–979.
13 Shibata H, Yoshioka Y, Ohkawa A, Minowa K, Mukai
Y, Abe Y, Taniai M, Nomura T, Kayamuro H,
Nabeshi H et al. (2008) Creation and X-ray structure
analysis of the tumor necrosis factor receptor-1-selective
mutant of a tumor necrosis factor-alpha antagonist.
J Biol Chem 283, 998–1007.
14 Luan X, Lu Q, Jiang Y, Zhang S, Wang Q, Yuan H,
Zhao W, Wang J & Wang X (2016) Crystal structure of
human RANKL complexed with its decoy receptor
opsteoprotegerin. J Immunol 189, 245–252.
15 Hymowitz SG, Christinger HW, Fuh G, Ultsch M,
O’Connell M, Kelley RF, Ashkenazi A & de Vos AM
(1999) Triggering cell death: the crystal structure of
Apo2L/TRAIL in a complex with death receptor 5.
Mol Cell 4, 563–571.
16 Jones EY, Stuart DI & Walker NPC (1989) Structure
of tumour necrosis factor. Nature 338, 225–228.
17 Liang S, Dai J, Hou S, Su L, Zhang D, Guo H, Hu S,
Wang H, Rao Z, Guo Y et al. (2013) Structural basis
for treating tumor necrosis factor a (TNFa)-associated
diseases with the therapeutic antibody infliximab. J Biol
Chem 288, 13799–13807.
18 Mongkolsapaya J, Grimes JM, Chen N, Xu XN, Stuart
DI, Jones EY & Screaton GR (1999) Structure of the
TRAIL-DR5 complex reveals mechanisms conferring
specificity in apoptotic initiation. Nat Struct Biol 6,
1048–1053.
19 Ta HM, Nguyen GTT, Jin HM, Choi J, Park H, Kim
N, Hwang H-Y & Kim KK (2010) Structure-based
development of a receptor activator of nuclear factor-
kappaB ligand (RANKL) inhibitor peptide and
molecular basis for osteopetrosis. Proc Natl Acad Sci
USA 107, 20281–20286.
20 Ito S, Wakabayashi K, Ubukata O, Hayashi S, Okada
F & Hata T (2002) Crystal structure of the extracellular
2511The FEBS Journal 284 (2017) 2501–2512 ª 2017 The Authors. The FEBS Journal published by John Wiley & Sons Ltd on behalf of
Federation of European Biochemical Societies.
Y. Wang et al. RANKL variants antagonizing osteoclastogenesis
domain of mouse RANK ligand at 2.2-A resolution.
J Biol Chem 277, 6631–6636.
21 Ito S & Hata T (2004) Crystal structure of RANK
ligand involved in bone metabolism. Vitam Horm 67,
19–33.
22 Reis CR, Van der Sloot AM, Szegezdi E, Natoni A,
Tur V, Cool RH, Samali A, Serrano L & Quax WJ
(2009) Enhancement of antitumor properties of
rhTRAIL by affinity increase toward its death
receptors. Biochemistry 48, 2180–2191.
23 Tur V, Van der Sloot AM, Reis CR, Szegezdi E, Cool
RH, Samali A, Serrano L & Quax WJ (2008) DR4-
selective tumor necrosis factor-related apoptosis-
inducing ligand (TRAIL) variants obtained by
structure-based design. J Biol Chem 283, 20560–20568.
24 Van der Sloot AM, Tur V, Szegezdi E, Mullally MM,
Cool RH, Samali A, Serrano L & Quax WJ (2006)
Designed tumor necrosis factor-related apoptosis-
inducing ligand variants initiating apoptosis exclusively
via the DR5 receptor. Proc Natl Acad Sci U S A 103,
8634–8639.
25 Mori H, Kitazawa R, Mizuki S, Nose M, Maeda S &
Kitazawa S (2002) RANK ligand, RANK, and OPG
expression in type II collagen-induced arthritis mouse.
Histochem Cell Biol 117, 283–292.
26 Whyte MP (2006) Paget’s disease of bone and genetic
disorders of RANKL/OPG/RANK/NF-kappaB
signaling. Ann N Y Acad Sci 1068, 143–164.
27 Lipton A, Uzzo R, Amato RJ, Ellis GK, Hakimian B,
Roodman GD & Smith MR (2009) The science and
practice of bone health in oncology: managing bone
loss and metastasis in patients with solid tumors. J Natl
Compr Canc Netw 7 (Suppl. 7), S1–S29; quiz S30.
28 Body J-J, Greipp P, Coleman RE, Facon T, Geurs F,
Fermand J-P, Harousseau J-L, Lipton A, Mariette X,
Williams CD et al. (2003) A phase I study of AMGN-
0007, a recombinant osteoprotegerin construct, in
patients with multiple myeloma or breast carcinoma
related bone metastases. Cancer 97, 887–892.
29 Higgs JT, Jarboe JS, Lee JH, Chanda D, Lee CM,
Deivanayagam C & Ponnazhagan S (2015) Variants of
osteoprotegerin lacking TRAIL binding for therapeutic
bone remodeling in osteolytic malignancies. Mol Cancer
Res 33, 395–401.
30 Naidu VGM, Dinesh Babu KR, Thwin MM, Satish
RL, Kumar PV & Gopalakrishnakone P (2013)
RANKL targeted peptides inhibit osteoclastogenesis
and attenuate adjuvant induced arthritis by inhibiting
NF-jB activation and down regulating inflammatory
cytokines. Chem Biol Interact 203, 467–479.
31 Banner DW, D’Arcy A, Janes W, Gentz R, Schoenfeld
HJ, Broger C, Loetscher H & Lesslauer W (1993)
Crystal structure of the soluble human 55 kd TNF
receptor-human TNFb complex: Implications for TNF
receptor activation. Cell 73, 431–445.
32 Mukai Y, Shibata H, Nakamura T, Yoshioka Y, Abe
Y, Nomura T, Taniai M, Ohta T, Ikemizu S,
Nakagawa S et al. (2009) Structure-function
relationship of tumor necrosis Factor (TNF) and its
receptor interaction based on 3D structural analysis of
a fully active TNFR1-selective TNF mutant. J Mol Biol
385, 1221–1229.
33 Wassenaar TA, Quax WJ & Mark AE (2008) The
conformation of the extracellular binding domain of
Death Receptor 5 in the presence and absence of the
activating ligand TRAIL: a molecular dynamics study.
Proteins 70, 333–343.
34 Neumann S, Bidon T, Bransch€adel M, Krippner-
Heidenreich A, Scheurich P & Doszczak M (2012) The
transmembrane domains of TNF-related apoptosis-
inducing ligand (TRAIL) receptors 1 and 2 co-regulate
apoptotic signaling capacity. PLoS One 7, e42526.
35 Miyazaki K & Takenouchi M (2002) Creating random
mutagenesis libraries using megaprimer PCR of whole
plasmid. Biotechniques 33, 1033–1034, 1036–1038.
36 Boersma YL, Chao G, Steiner D, Wittrup KD &
Pl€uckthun A (2011) Bispecific Designed Ankyrin
Repeat Proteins (DARPins) targeting epidermal growth
factor receptor inhibit A431 cell proliferation and
receptor recycling. J Biol Chem 286, 41273–41285.
37 Duan L, de Vos P, Fan M & Ren Y (2008) Notch is
activated in RANKL-induced osteoclast differentiation
and resorption. Front Biosci 13, 7064–7071.
Supporting information
Additional Supporting Information may be found
online in the supporting information tab for this
article:
Table S1. Absolute numbers of normal and giant
osteoclasts per RANKL treatment (experiment 1).
Table S2. Absolute numbers of normal and giant
osteoclasts per RANKL treatment (experiment 2).
2512 The FEBS Journal 284 (2017) 2501–2512 ª 2017 The Authors. The FEBS Journal published by John Wiley & Sons Ltd on behalf of
Federation of European Biochemical Societies.
RANKL variants antagonizing osteoclastogenesis Y. Wang et al.
